This technology is a computational monitoring platform that uses coherence factor-based passive acoustic mapping to monitor focused ultrasound treatment.
Transcranial focused ultrasound (FUS) is used for opening the blood-brain barrier for drug delivery or tumor ablation in the brain. To ensure safety and efficiency for these operations, transcranial passive cavitation detection is used to map cavities in the brain. The ultrasound used in FUS has a frequency lower than 3 MHz due to attenuation of the skull, resulting in poor spatial resolution and challenges in real-time implementation due to integration of time samples.
This technology utilizes coherent factor-based passive acoustic mapping (PAM) to monitor FUS treatment in real-time. The use of the coherence weighting factor ensures that the signal is close to 1 when coherent and close to 0 when incoherent. This method improves the axial resolution of PAM, while enhancing the spatial resolution and reducing the noise. This technology also benefits from a low computational cost, allowing for its use in real-time with transcranial FUS treatment.
This technology has been validated in pediatric patients.
Patent Pending (US20240307080)
IR CU22079
Licensing Contact: Dovina Qu